Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS
pharmaceutical investing Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS (eflapegrastim) Data
Premier American Uranium Reports Results Following Annual General and Special Meeting of Shareholders
